The new facility in India has been designed to be environmentally conscious and with a Zero Liquid Discharge system
Ground breaking ceremonies with Dr Muhammed Majeed, Mr and Mrs Shaheen Majeed, Dr Anju Majeed, and members of the Sami-Sabinsa Group management and staff.
Sami-Sabinsa Group has commenced building of a new API manufacturing unit at the Pharma SEZ Industrial Area in India. This latest facility in the Hassan, Karnatake area will cost $30 million and is part of the group’s strategy to expand existing ingredient growth, and focus on innovating new products.
This will be the company’s eighth manufacturing facility.
Commenting at the groundbreaking ceremony, Dr Muhammed Majeed, Founder and Chairman of Sami-Sabinsa, said: “We have been doing business in India for nearly three decades now, and our business has grown rapidly over the years. The upcoming production facility at Hassan will not only empower us to cater to the entire global market with patented and off-patent API products but will also play a vital role inboosting the export sales of the Sami-Sabinsa Group and help in doubling the company revenue.”
The first phase covering 430,556 sqft of this world-class API manufacturing unit will have a production capacity of more than 300 tonnes per annum.
The environmentally conscious, Zero Liquid Discharge (ZLD) facility will combine user comfort, energy efficiency, responsible water management, and biodiversity development.
The facility, which will be 100% cGMP and compliant with regulatory requirements, is scheduled for commissioning by 2021 and is expected to generate employment for approximately 400 people in and around Hassan.